A patent specification is, in principle, a disclosure document. It tells the world what the invention is, how it works, and what variants and combinations the inventor has conceived. The claims that follow — the numbered sentences at the end — are drawn from that disclosure, but they need not exhaust it. There may be subject matter described in the specification, in equal technical detail and with equal inventive substance, that the applicant has chosen not to claim immediately — whether because prosecution strategy counselled a narrower initial claim set, because the commercial significance of the subject matter was not yet apparent, or because the applicant wished to defer those claims to a later filing without losing the priority date.

This practice is not unusual. In pharmaceutical and biotechnology prosecution, it is near-universal. The initial claim set will typically reflect the most commercially valuable compound or formulation; the specification will describe the broader field of which the claimed compound is one example. The balance of the field — the dosage forms, the combinations, the alternative routes of administration — sits disclosed but unclaimed, available in the specification and unavailable in the grant.

When that reserved subject matter later becomes commercially significant, the mechanism is Section 16 of the Patents Act — the divisional application. The condition is that the divisional does not introduce new matter: it can only claim what the parent disclosed, not what it did not. Where the applicant has done its drafting work at the outset, the divisional is a clean route. Whether it survived, however, has for years depended not on the quality of the parent's disclosure but on how the Indian Patent Office chose to read Section 16.

Where the Patent Office Had Been Drawing the Line

The Indian Patent Office had, for years, applied a reading of Section 16 that went on to make this mechanism significantly less useful than its text warranted. Its position was that a divisional was maintainable only where the parent application disclosed a plurality of inventions through its claims — that is, where the parent's claim set, not merely its specification, contained more than one invention. An applicant who had chosen to claim narrowly at the outset, or who had narrowed claims during prosecution to overcome an objection, found the divisional route effectively closed, even where the specification was broad enough to sustain it with ease.

For pharmaceutical and biotechnology applicants, whose specifications are by design broader than their initial claims, this reading was a systematic foreclosure of subject matter that the statute plainly permitted to be pursued. The structure of Section 16 — which allows a divisional wherever the parent discloses a plurality of inventions — does not, on its face, restrict the assessment to the claims. The Office was reading a limitation into the provision that the legislature had not placed there.

How Syngenta Had Already Moved the Line

In 2023, a Full Bench of the Delhi High Court decided Syngenta v. Controller of Patents and held that plurality of inventions under Section 16 is assessed on the basis of the parent's full specification — not the parent's claims. The ruling aligned India with the Patent Cooperation Treaty's approach and with the position at the European Patent Office. Subject matter disclosed in the specification but reserved from the initial claim set remained available for divisional filing.

But Syngenta bound Delhi, and only Delhi. The Patent Office's officers filing in Calcutta continued to apply the older, narrower reading. The result was that the maintainability of a divisional application depended not on the quality of the parent's disclosure but on the geography of the parent's prosecution — a forum-dependency that had no basis in the statute and produced distortions in how applicants structured their filing strategies.

What the Calcutta High Court Did

Pharmacyclics had filed a divisional covering combinations involving ibrutinib — its BTK-inhibitor cancer drug — that were disclosed in the parent specification but absent from the parent's original claim set. The Deputy Controller refused the application on the ground that the combination was not present in the parent's claims. Pharmacyclics appealed.

The Calcutta High Court set the refusal aside, adopting the Syngenta reasoning in full: a divisional is maintainable so long as the claimed subject matter is supported by the disclosure in the parent specification, without the requirement that it have appeared in the parent's original claim set. The matter was remanded for examination on merits. With both Calcutta and Delhi now aligned on this reading, divisional maintainability on the basis of parent-specification disclosure is, for practical purposes, the position across the country.

Why the Ruling Changes the Terrain

The ruling matters most to applicants whose specifications routinely describe more than they initially claim — which, in the pharmaceutical and biotechnology sectors, means virtually every portfolio of significance. Compound classes, combinations, dosage forms, delivery systems: the specification will often cover the full field while the initial claims focus on a narrower commercial priority. The balance of the field is now available for carve-out through divisional filings, up to the date of the parent's grant, regardless of whether it appeared in the parent's original claims.

The forum-dependency that had distorted prosecution decisions is removed. Applicants drafting new applications can write broader specifications with greater confidence that disclosed-but-unclaimed subject matter remains available for the future. That is a meaningful shift in how first-filing portfolios are built — and it goes on to affect not only the prosecution of individual patents but the strategic architecture of entire portfolios in sectors where the gap between what is disclosed and what is initially claimed is, by design, substantial.

The Takeaway

If your Indian patent portfolio includes applications where the specification describes subject matter you chose not to claim at the outset, that subject matter is not lost. A divisional application, properly grounded in the parent's specification, is now maintainable at the Patent Office — whether the parent proceeds in Delhi, Calcutta, or anywhere else.

The disclosure carries forward. The claim catches up.